Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SYH2053 injection in adults with heterozygous familial hypercholesterolemia
CTR20260676Phase 3Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SYH2053 in heterozygous familial hypercholesterolemia (HeFH), sponsored by CSPC Zhongnuo Pharmaceutical. Started May 2026; status: active.
02
Drugs
SYH2053
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on CTR20260676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260676.